Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COUGH-1: Gefapixant in Chronic Cough
NCT03449134Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of gefapixant in chronic cough, sponsored by Merck & Co.. Started Mar 2018; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT03449134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449134.